Shares of Cryolife CRY rose in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share increased 137.50% year over year to $0.03, which beat the estimate of ($0.09).
Revenue of $71,087,000 rose by 7.01% year over year, which beat the estimate of $62,980,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Cryolife hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Apr 29, 2021
Time: 04:30 PM
ET Webcast URL: https://www.cryolife.com/events/
Technicals
Company's 52-week high was at $26.60
52-week low: $16.13
Price action over last quarter: down 5.78%
Company Overview
Cryolife Inc is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures focused on aortic repair. The company has two reportable segments namely Medical devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue, On-X products, JOTEC products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular tissues. It generates a majority of its revenue from the Medical Devices segment. Geographically, the company generates a majority of its revenue from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.